FDA staffers defend Aduhelm approval in JAMA editorialThree FDA figures at the centre of the fallout over the approval Biogen and Eisai’s Alzheimer’s disease therapy Share XFDA staffers defend Aduhelm approval in JAMA editorialhttps://pharmaphorum.com/news/fda-staffers-defend-aduhelm-approval-in-jama-editorial/
US starts review of Aduhelm coverage amid fears of Medicare hitThe US government has started a review of how Biogen and Eisai’s pricey new Alzheimer’s disease therapy Aduhelm Share XUS starts review of Aduhelm coverage amid fears of Medicare hithttps://pharmaphorum.com/news/us-starts-review-of-aduhelm-coverage-amid-fears-of-medicare-hit/
Aduhelm approval controversy dials up as FDA seeks probeIn another twist to the Aduhelm approval tale, FDA’s Janet Woodcock has called for an independent investigation into Share XAduhelm approval controversy dials up as FDA seeks probehttps://pharmaphorum.com/news/aduhelm-approval-controversy-dials-up-as-fda-seeks-probe/
FDA whittles back Aduhelm approval amid concern over broad labelOne of the criticisms levelled at the FDA over its approval of Biogen and Eisai’s Alzheimer’s disease drug Share XFDA whittles back Aduhelm approval amid concern over broad labelhttps://pharmaphorum.com/news/fda-whittles-back-aduhelm-approval-amid-concern-over-broad-label/
Amid outcry over Aduhelm price, Biogen says it may consider ‘adjustment’Biogen has hinted that it may consider altering the price of its controversially-approved Alzheimer’s therapy Aduhelm – but Share XAmid outcry over Aduhelm price, Biogen says it may consider ‘adjustment’https://pharmaphorum.com/news/amid-outcry-over-aduhelm-price-biogen-says-it-may-consider-adjustment/
BMS pays $650m upfront for Eisai’s first ADC candidate for cancerJapan’s Eisai has hit the jackpot with its first ever antibody-drug conjugate (ADC) drug candidate, attracting a licensing Share XBMS pays $650m upfront for Eisai’s first ADC candidate for cancerhttps://pharmaphorum.com/news/bms-pays-650m-upfront-for-eisais-first-adc-candidate-for-cancer/
Merck gets confirmatory trial win for Keytruda in endometrial cancerMerck & Co’s conditional FDA approval for checkpoint inhibitor Keytruda in endometrial cancer looks secure, thanks to a Share XMerck gets confirmatory trial win for Keytruda in endometrial cancerhttps://pharmaphorum.com/news/merck-gets-confirmatory-trial-win-for-keytruda-in-endometrial-cancer/
Merck gets a leg-up for Keytruda in first-line kidney cancerNew phase 3 data have shored up the position of Merck & Co’s cancer immunotherapy Keytruda in the Share XMerck gets a leg-up for Keytruda in first-line kidney cancerhttps://pharmaphorum.com/news/merck-gets-a-leg-up-for-keytruda-in-first-line-kidney-cancer/
Could Lilly’s donanemab readout in Alzheimer’s boost Biogen’s prospects?When Eli Lilly reported results for donanemab in Alzheimer’s disease earlier this week it was hailed as a Share XCould Lilly’s donanemab readout in Alzheimer’s boost Biogen’s prospects?https://pharmaphorum.com/news/could-lillys-alzheimers-drug-readout-boost-biogens-prospects/
